Abata Therapeutics Appoints Sandy Lazzari as Chief People Officer

Lazzari to lead talent strategy, recruitment, and retainment efforts and execute on employee growth plan

BOSTON, April 28, 2022 –Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that it has strengthened its leadership team with the addition of Sandy Lazzari as Chief People Officer. At Abata, she will drive talent strategy efforts to attract, hire, develop, reward, and retain the best people.

“At Abata, people are our greatest asset, and only through our team’s collective talents and efforts can we successfully advance an entirely new approach to treating multiple sclerosis, Type 1 diabetes, and other severe autoimmune and inflammatory diseases,” said Samantha Singer, M.S., M.B.A., president and chief executive officer of Abata. “Sandy will help us continue to build an exceptional team and cultivate a working environment designed to maximize the potential of our Treg cell therapies for patients who need better treatment options. We welcome Sandy to the team and look forward to her contributions.”

“Abata is as deeply committed to the importance of its people and culture as it is to its science and mission, which in my experience is what sets a company up for success,” said Lazzari. “I’ve been as impressed by their rigorous science, which could offer patients suffering from autoimmune diseases new safe, robust and durable therapies, as I am with the character and values of the team. I’m honored to join this distinguished group and help build what I believe can become a remarkable company with the potential to truly change patients’ lives.”

Sandy Lazzari has more than 25 years of experience in employee growth, engagement and belonging strategies across a range of life sciences and high-tech companies. Prior to joining Abata, Sandy was the Vice President of People and Culture at PlateletBio, a life science company developing a new platform of cell-based therapies inspired by platelet biology. Before joining PlateletBio, Sandy led the Human Resources organizations at several other life science companies including Emulate Bio, Kala Pharmaceuticals, OvaScience, and Quanterix. Sandy started her work in the life sciences at Millipore, where she spent eight years in global HR roles including as the Global Business Partner for their largest business unit. Prior to her work in life sciences, Sandy spent 10 years working in several HR roles at Avid Technology. Sandy holds a dual Bachelor’s degree in Psychology and Business Management from the University of Southern New Hampshire, is a Certified Executive Coach, and holds several Human Resources certifications including SPHR (Strategic Professional in Human Resources) and HCS (Human Capital Strategist). 

About Abata Therapeutics

Abata Therapeutics is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases. Founded by pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers, Abata has developed a differentiated product engine to create engineered Treg cell therapies that are tissue-specific, robust, and durable. In addition to its lead program in progressive multiple sclerosis (MS), Abata has programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM) – two additional tissue-specific autoimmune diseases with substantial unmet need and a strong rationale for Abata’s Treg approach. The company was launched in 2021 by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara BioCapital, and the JDRF T1D Fund. Abata is based in Cambridge, Mass. Please visit abatatx.com or follow us on Twitter or LinkedIn for more information.

Media Contact
Cory Tromblee
Scient PR

Investor Contact
Julie Seidel
Stern Investor Relations, Inc.

Back to all posts